News

Millennial & Gen X Moms Struggle with the Mental Load, Spending a Staggering 520 Hours Per Year on Invisible Labor

SAN FRANCISCO, May 20, 2024 /PRNewswire/ — Coinciding with Motherhood Mental Health Awareness week, Gether is proud to announce its official launch in the United States, presenting a digital solution tailored to drastically reduce the […]

No Picture
News

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today […]

No Picture
News

AmplifyBio and Xcell Biosciences Announce Partnership to Manufacture Solid Tumor-Targeting TCR-T Cell Therapy

SAN FRANCISCO & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, and AmplifyBio, a rapidly growing contract development and manufacturing organization, today announced […]

No Picture
News

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that the company will present the first preclinical data on the company’s […]

No Picture
News

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led […]